Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OPT | US
-0.12
-2.61%
Healthcare
Biotechnology
30/06/2024
04/10/2024
4.48
4.52
4.59
4.48
Opthea Limited a clinical stage biopharmaceutical company develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth as well as vascular leakage. Its lead asset is OPT 302 a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME) as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra Australia.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Strong Sharpe Ratio (> 1.2)
Weakness based on declining price with high volume
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
79.9%1 month
70.5%3 months
60.2%6 months
63.8%-
6.73
4.31
-2.65
1.06
-0.73
5.06K
-
-191.82M
746.87M
746.87M
-
-164.54K
-
-68.30
-3.38K
6.52
0.06
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.32
Range1M
2.07
Range3M
3.02
Rel. volume
1.22
Price X volume
164.33K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 17.77 | 815.72M | -1.44% | n/a | 6.45% |
Adeptus Health Inc | ADPT | Biotechnology | 5.52 | 814.05M | 7.39% | n/a | 93.65% |
Nuvation Bio Inc | NUVB | Biotechnology | 2.41 | 806.82M | 9.05% | n/a | 112.61% |
Immunome Inc | IMNM | Biotechnology | 13.17 | 790.92M | -2.44% | n/a | 1.09% |
89bio Inc | ETNB | Biotechnology | 7.19 | 772.52M | -0.96% | n/a | 5.31% |
Capricor Therapeutics Inc | CAPR | Biotechnology | 21.65 | 765.05M | 31.05% | n/a | 45.32% |
TNGX | TNGX | Biotechnology | 6.98 | 747.87M | -0.85% | n/a | 15.28% |
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.73 | 0.76 | Cheaper |
Ent. to Revenue | 5,061.70 | 3,674.48 | Expensive |
PE Ratio | - | 38.01 | - |
Price to Book | 4.31 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 60.20 | 74.67 | Par |
Debt to Equity | -2.65 | -1.82 | Cheaper |
Debt to Assets | 1.06 | 0.26 | Expensive |
Market Cap | 746.87M | 3.73B | Emerging |